Myriad Genetics, Inc. (MYGN)
3.18
-0.05
(-1.55%)
USD |
NASDAQ |
Sep 04, 15:31
Myriad Genetics Cash from Investing (Quarterly) : -3.20M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.20M |
| March 31, 2026 | -6.50M |
| December 31, 2025 | -6.00M |
| September 30, 2025 | -6.20M |
| June 30, 2025 | -6.90M |
| March 31, 2025 | -8.30M |
| December 31, 2024 | -5.90M |
| September 30, 2024 | 7.50M |
| June 30, 2024 | -6.40M |
| March 31, 2024 | -7.10M |
| December 31, 2023 | -12.00M |
| September 30, 2023 | -2.50M |
| June 30, 2023 | 11.80M |
| March 31, 2023 | 34.60M |
| December 31, 2022 | -35.60M |
| September 30, 2022 | 11.40M |
| June 30, 2022 | -12.00M |
| March 31, 2022 | -41.30M |
| December 31, 2021 | -25.90M |
| September 30, 2021 | 291.00M |
| June 30, 2021 | 1.10M |
| March 31, 2021 | 8.20M |
| June 30, 2020 | 10.30M |
| March 31, 2020 | 24.80M |
| December 31, 2019 | -8.70M |
| Date | Value |
|---|---|
| September 30, 2019 | -7.10M |
| June 30, 2019 | 4.50M |
| March 31, 2019 | -3.80M |
| December 31, 2018 | -8.10M |
| September 30, 2018 | -279.00M |
| June 30, 2018 | 8.90M |
| March 31, 2018 | -0.50M |
| December 31, 2017 | -4.30M |
| September 30, 2017 | -15.20M |
| June 30, 2017 | 4.30M |
| March 31, 2017 | 9.50M |
| December 31, 2016 | -2.10M |
| September 30, 2016 | -158.00M |
| June 30, 2016 | -43.80M |
| March 31, 2016 | -16.10M |
| December 31, 2015 | -40.50M |
| September 30, 2015 | 9.00M |
| June 30, 2015 | -2.813M |
| March 31, 2015 | 24.88M |
| December 31, 2014 | -8.748M |
| September 30, 2014 | 27.58M |
| June 30, 2014 | -19.86M |
| March 31, 2014 | -0.471M |
| December 31, 2013 | 10.72M |
| September 30, 2013 | -8.057M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Natera, Inc. | -63.43M |
| Sera Prognostics, Inc. | 6.394M |
| BioRestorative Therapies, Inc. | 0.9684M |
| CareDx, Inc. | 280.59M |
| Exagen, Inc. | -0.543M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.30M |
| Cash from Financing (Quarterly) | 2.20M |
| Free Cash Flow | -14.20M |
| Free Cash Flow Per Share (Quarterly) | -0.1213 |
| Free Cash Flow to Equity (Quarterly) | -10.50M |
| Free Cash Flow to Firm (Quarterly) | -7.342M |
| Free Cash Flow Yield | -4.76% |